Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: A multicentre study

AIDS

Volumn 14, Issue 11, 2000, Pages 1655-1656

  De Luca, Andrea ^a   Baldini, Francesco ^a   Cingolani, Antonella ^a   Di Giambenedetto, Simona ^a   Zaccarelli, Mauro ^b   Tozzi, Valerio ^b   Ammassari, Adriana ^a   Murri, Rita ^a   Antinori, Andrea ^b  

^a UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DIDANOSINE; GLUCOSE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PREDNISONE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD CHEMISTRY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; LIPODYSTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROLITHIASIS; PARESTHESIA; PRIORITY JOURNAL; RASH; RISK BENEFIT ANALYSIS; STEVENS JOHNSON SYNDROME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; NEVIRAPINE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; VIRAL LOAD;

EID: 0033821022     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200007280-00022     Document Type: Article

References (10)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
3. Maintainance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) Study
4. Maintainance antiretroviral therapies in HIV-1 infected subjects with undetectable plasma HIV RNA after triple drug therapy
5. A randomized trial of three maintainance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1 infected patients
6. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
7. Substituting nevirapine for protease inhibitors because of intolerance
8. A randomized, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: The INCAS Trial.Italy, The Netherlands, Canada and Australia Study
9. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults.Study 006 Team
10. A multi-center, randomized, open-label, comparative trial of the clinical benefit of switching the protease inhibitor (PI) by nevirapine (NVP) in HAART-experienced patients suffering lipodystrophy: 36-week follow up